Les$vaccins$antiCovid 19Suivi%de%l’OMS%du%13%aout%2021

https://www.who.int/publications/m/item/draft@landscape@of@covid@19@candidate@vaccines

Les$vaccins$en$développement

275Préclinique.

184

Clinique.91

23.avril.2021.

294Préclinique.

184

Clinique.110

13.aout.2021.

Les$vaccins$en$phase$clinique

Phase&44%

Phase&317%

Phase&2/38%

Phase&210%

Phase&1/227%

Phase&134%

VACCINS''EN'PHASE'CLINIQUE'AVRIL'2021

Phase'134%

Phase'19224%

Phase'29%

Phase'2939%

Phase'317%

Phase'47%

VACCINS'EN'PHASE'CLINIQUE'AOUT'2021

IV

PS

VLP

PS

VVnr

ARN

ADN

Les$vaccins$en$phase$clinique

Avril&2021

Sinovac Research and.Development Co.,.Ltd.(avril.2021).Virus.inactivé.(IV)AstraZeneca +.University of.Oxford.(avril.2021) Adénovirus.(VVnr)Moderna +.National.Institute.of.Allergy and.Infectious Diseases (NIAID).(avril.2021).ARNPfizer/BioNTech +.Fosun Pharma.(avril.2021).ARN

Aout%2021

Sinopharm +.China.National.Biotec Group.Co.+.Beijing.Institute.of.BiologicalProducts Virus.inactivé.(IV)CanSino Biological Inc./Beijing.Institute.of.Biotechnology Adénovirus.(VVnr)Janssen.Pharmaceutical.Adénovirus.(VVnr)Moderna +.National.Institute.of.Allergy and.Infectious Diseases (NIAID).ARN.nouvelle.formulationPfizer/BioNTech +.Fosun Pharma.(avril.2021).ARN

Disponible.à.la.vaccination.en.phase.4

RNA37%

VVnr38%

IV25%

VACCIN%DISPONIBLE%EN%PHASE%4

Les$vaccins$en$phase$cliniqueEn#phase#3#Aout%2021

VVnr5%

IV37%

RNA11%

PS42%

DNA5%

EN%PHASE%3

DNA Zydus CadilaIV Sinopharm +#China#National#Biotec Group#Co#+#Wuhan#Institute#of#Biological ProIV Institute#of#Medical Biology +#Chinese Academy of#Medical SciencesIV Research Institute#for#Biological Safety Problems,#Rep of#KazakhstanIV Bharat Biotech International#LimitedIV Shenzhen#Kangtai Biological Products Co.,#Ltd.#IV Valneva,#National#Institute#for#Health Research,#United#KingdomIV Erciyes University,#TurkeyPS NovavaxPS Anhui#Zhifei Longcom Biopharmaceutical +#Institute#of#Microbiology,#ChinesePS Sanofi#Pasteur#+#GSKPS Instituto Finlay#de#VacunasPS Federal Budgetary Research Institution#State#Research Center#of#Virology andPS West#China#Hospital +#Sichuan#UniversityPS Center#for#Genetic Engineering#and#Biotechnology (CIGB)#PS Nanogen Pharmaceutical#BiotechnologyRNA CureVac AGRNA Academy of#Military Science#(AMS),#Walvax Biotechnology and#Suzhou#AbogenVVnr "Gamaleya Research Institute#;#Health Ministry#of#the#Russian (Sputnik V)

Les$vaccins$en$phase$cliniqueIV11%

RNA34%

PS33%

VLP22%

Phase22

VVnr17%

IV4%

RNA17%

PS50%

DNA12%

Phase2291

VVnr19%

IV14%

RNA17%

PS28%

DNA8%

VVr3%

VLP5%

VVr2+2APC6%

Phase21

VVnr20%

PS50%

DNA20%

VVr10%

Phase2293

Les$types$de$vaccins$en$clinique

Virus&inactivé&ou&atténué15%

Vecteur&viral24%

ARN&Messager13%

ADN11%

Protéine&recombinante

32%

VLP5%

VVnr16%

IV15%

RNA17%

PS36%

DNA8%

VVr2%

VLP4%

VVr5+5APC2%

Vaccin5par5type5de5plateforme

Les$vaccins$à$ARN$messagerAvril&2021 Aout&2021

Phase&42&) 3

Moderna +&National&Institute&of&Allergy and&Infectious Diseases (NIAID)Pfizer/BioNTech +&Fosun Pharma&

Moderna +&National&Institute&of&Allergy and&Infectious Diseases(NIAID)&(1273&et&1273.351)Pfizer/BioNTech +&Fosun Pharma&

Phase&31&) 2

CureVac AG CureVac AGAcademy of&Military Science&(AMS),&Walvax Biotechnology and&Suzhou&Abogen Biosciences

Phase&2) 30&– 1

Moderna +&National&Institute&of&Allergy and&Infectious Diseases(NIAID)&(1273&+&1273.351)

Phase&23&) 2

Arcturus TherapeuticsAcademy of&Military Science&(AMS),&WalvaxBiotechnology and&Suzhou&Abogen Biosciences

Arcturus TherapeuticsSanofi&Pasteur&and&Translate&Bio

Phase&1)2 Sanofi&Pasteur&and&Translate&BioDaiichi Sankyo Co.,&Ltd.

Daiichi Sankyo Co.,&Ltd.Elixirgen Therapeutics,&Inc

Phase&1 Imperial&College LondonChulalongkorn UniversityProvidence&TherapeuticsGlaxoSmithKlineModerna +&National&Institute&of&Allergy and&InfectiousDiseases (NIAID)

Imperial&College LondonChulalongkorn UniversityProvidence&TherapeuticsGlaxoSmithKlineModerna +&National&Institute&of&Allergy and&Infectious Diseases (NIAID)Shanghai&East&Hospital and&Stemirna TherapeuticsMRC/UVRI&and&LSHTM&Uganda&Research Unit

Les$vaccins$à$ADN

Avril&2021 Aout&2021Phase&4Phase&31&* 1

Zydus Cadila Zydus Cadila

Phase&2* 32&– 2

AnGes +&Takara Bio&+&Osaka&UniversityInovio Pharmaceuticals&+&International&Vaccine&Institute&+&Advaccine (Suzhou)&Biopharmaceutical Co.,&Ltd

AnGes +&Takara Bio&+&Osaka&UniversityInovio Pharmaceuticals&+&International&Vaccine&Institute&+&Advaccine (Suzhou)&Biopharmaceutical Co.,&Ltd

Phase&2Phase&1*23&* 3

Takis&+&Rottapharm BiotechGeneOne Life&Science,&Inc.Genexine Consortium

Takis&+&Rottapharm BiotechGeneOne Life&Science,&Inc.Genexine Consortium

Phase&14&* 4

University of&Sydney,&Bionet Co.,&LtdSymvivo CorporationProvidence&Health &&ServicesEntos Pharmaceuticals&Inc.

University of&Sydney,&Bionet Co.,&LtdSymvivo CorporationProvidence&Health &&ServicesEntos Pharmaceuticals&Inc.

Les$vaccins$à$virus$atténué$ou$inactivéAvril&2021 Aout&2021

Phase&4 Sinovac Research and&Development Co.,&Ltd Sinopharm +&China&National&Biotec Group&Co&+&Wuhan&Institute&of&Biological Products

Phase&34&D 6

Sinopharm +&China&National&Biotec Group&Co&+&Wuhan&Institute&of&Biological ProductsInstitute&of&Medical Biology +&Chinese Academy of&Medical SciencesResearch Institute&for&Biological Safety Problems,&Rep of&KazakhstanBharat Biotech International&Limited

Sinopharm +&China&National&Biotec Group&Co&+&Wuhan&Institute&of&Biological ProductsInstitute&of&Medical Biology +&Chinese Academy of&MedicalSciencesBharat Biotech International&LimitedErciyes UniversityValneva,&National&Institute&for&Health Research,&United&KingdomShenzhen&Kangtai Biological Products Co.,&Ltd.&

Phase&2D 3 Shifa Pharmed Industrial Co Shifa Pharmed Industrial Co

Phase&1D21&D 2

Valneva,&National&Institute&for&Health Research,&United&Kingdom

The&Government Pharmaceutical&Organization (GPO);&PATH;&DynavaxKM&Biologics Co.,&Ltd.

Phase&13&D 4

Codagenix/Serum Institute&of&IndiaOrganization of&Defensive Innovation&and&ResearchMeissa Vaccines,&Inc.

Organization of&Defensive Innovation&and&ResearchKocak Farma,&TurkeyThe&Scientific&and&Technological Research Council&of&TurkeyLaboratorio AviDMex

Les$vaccins$à$vecteur$viral$non$répliquant

Avril&2021 Aout&2021Phase&4 AstraZeneca +&University of&Oxford AstraZeneca +&University of&Oxford

Janssen&PharmaceuticalCanSino Biological Inc./Beijing&Institute&of&Biotechnology

Phase&31&F 1

Gamaleya Research Institute&;&Health Ministry&of&the&Russian Federation

Gamaleya Research Institute&;&Health Ministry&of&the&Russian Federation

Phase&2F 3 AstraZeneca +&University of&Oxford&(variant&beta)

Phase&2

Phase&1F20&F 4

ImmunityBio,&IncCellid Co.,&Ltd.Institute&of&Vaccines&and&Medical Biologicals,&VietnamGerman Center&for&Infection&Research

Phase&16&F 6

Gritstone OncologyBharat Biotech International&LimitedAltimmune,&Inc.City&of&Hope&Medical Center&+&National&Cancer&InstituteUniversity of&Munich&(LudwigFMaximilians)Vaxart

Gritstone OncologyBharat Biotech International&LimitedCity&of&Hope&Medical Center&+&National&Cancer&InstituteUniversity of&Munich&(LudwigFMaximilians)Tetherex Pharmaceuticals&CorporationCyanVac LLC

Les$vaccins$à$vecteur$viral$non$répliquant

Avril&2021 Aout&2021Phase&4 AstraZeneca +&University of&Oxford AstraZeneca +&University of&Oxford

Janssen&PharmaceuticalCanSino Biological Inc./Beijing&Institute&of&Biotechnology

Phase&31&F 1

Gamaleya Research Institute&;&Health Ministry&of&the&Russian Federation

Gamaleya Research Institute&;&Health Ministry&of&the&Russian Federation

Phase&2F 3 AstraZeneca +&University of&Oxford&(variant&beta)

Phase&2

Phase&1F20&F 4

ImmunityBio,&IncCellid Co.,&Ltd.Institute&of&Vaccines&and&Medical Biologicals,&VietnamGerman Center&for&Infection&Research

Phase&16&F 6

Gritstone OncologyBharat Biotech International&LimitedAltimmune,&Inc.City&of&Hope&Medical Center&+&National&Cancer&InstituteUniversity of&Munich&(LudwigFMaximilians)Vaxart

Gritstone OncologyBharat Biotech International&LimitedCity&of&Hope&Medical Center&+&National&Cancer&InstituteUniversity of&Munich&(LudwigFMaximilians)Tetherex Pharmaceuticals&CorporationCyanVac LLC

Les$vaccins$à$protéine$recombinanteAvril&2021 Aout&2021

Phase&37&) 9

NovavaxAnhui&Zhifei Longcom Biopharmaceutical +&Institute&of&Microbiology,&Chinese Academy of&Sciences&Sanofi&Pasteur&+&GSKInstituto Finlay&de&VacunasFederal Budgetary Research Institution&State&Research Center&of&Virology and&Biotechnology "Vector »Center&for&Genetic Engineering&and&Biotechnology

NovavaxAnhui&Zhifei Longcom Biopharmaceutical +&Institute&of&Microbiology,&Chinese Academy of&SciencesSanofi&Pasteur&+&GSKInstituto Finlay&de&VacunasFederal Budgetary Research Institution&State&Research Center&of&Virology and&Biotechnology "Vector"West&China&Hospital +&Sichuan&UniversityCenter&for&Genetic Engineering&and&Biotechnology (CIGB)&Nanogen Pharmaceutical&Biotechnology

Phase&2) 32&) 2

Clover Biopharmaceuticals Inc./GSK/DynavaxCSL&Ltd.&+&Seqirus +&University of&QueenslandVaxinity

Clover Biopharmaceuticals Inc./GSK/DynavaxVaxxinity

Phase&23&) 6

Medigen Vaccine&Biologics +&Dynavax +&National&Institute&of&Allergy and&Infectious Diseases (NIAID)West&China&Hospital +&Sichuan&UniversityRazi Vaccine&and&Serum Research Institute

Medigen Vaccine&Biologics +&Dynavax +&National&Institute&of&Allergyand&Infectious Diseases (NIAID)Razi Vaccine&and&Serum Research InstituteClover Biopharmaceuticals Inc AUS&PytInstituto Finlay&de&VacunasGuangdong&Provincial&Center&for&Disease Control&and&Prevention/Gaozhou Center&for&Disease Control&and&Prevention

Phase&1)2&et&1

17 20

Les$autres$vaccins

VLP LAV VVnr +(APC VVr +(APCPhase&3&et&2&*3 1

Phase&2&et&1*2 3 1

Phase&1 1 2 1 1